Sarepta Gene Therapy Halt - Search News

Order byBest matchMost fresh

News

Gene Therapy Stays on Market Despite FDA Request

MedPage Today · 2h

Drugmaker Refuses FDA's Request to Pull Gene Therapy Tied to Patient Deaths

The agency also revoked Sarepta's platform technology designation for AAVrh74 Friday and issued a safety communication saying the agency was investigating the three deaths due to acute liver failure following treatment with Sarepta's AAVrh74 gene therapies.

Continue reading

· 2d · on MSN

Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths

· 2d · on MSN

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

9hon MSN

Sarepta extends losses premarket after refusing FDA’s halt request

Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...

6h

Sarepta Therapeutics: Why Is SRPT Stock Crashing?

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results